Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This BVD-523-ABC study builds on the safety and clinical activity experience of previous
studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of
patients with specific genetic alterations and tumor histologies that result in aberrant MAPK
pathway signaling. Early clinical data have demonstrated anti-tumor activity with ulixertinib
treatment and have identified specific groups of patients for whom additional development is
warranted.